C-X-C RECEPTOR 4 {CXCR4} METASTASIS KANKER PAYUDARA
| Main Authors: | Sudarsa, I Wayan, Sutirta Yasa, I Wayan Putu |
|---|---|
| Format: | Article info application/pdf eJournal |
| Bahasa: | eng |
| Terbitan: |
PERHIMPUNAN DOKTER SPESIALIS PATOLOGI KLINIK INDONESIA
, 2016
|
| Subjects: | |
| Online Access: |
http://www.indonesianjournalofclinicalpathology.or.id/index.php/patologi/article/view/408 http://www.indonesianjournalofclinicalpathology.or.id/index.php/patologi/article/view/408/153 |
Daftar Isi:
- The chemokine receptors CXCR4 (chemokine C-X-C motif receptor 4) and its ligand (stromal derived factor-1/SDF-1 or chemokine motif ligand 12/CXCL12) play an important role in cancer invasion and metastasis. The spread of breast cancer follows a nonrandom metastatic pattern typically involving spread of tumor to regional lymph nodes, lung, liver, and/or bone marrow. The ligand for CXCR4, SDF-1/CXCL12, is highly expressed by stromal fibroblasts within these tissues. The chemokine receptors CXCR4 is structurally related to chemokine receptor belonging to the superfamily of the seven transmembrane G-protein coupled receptors. In contrast to normal breast tissue, breast cancer cells typically express high levels of functional CXCR4 receptors that can direct chemotaxis and invasive responses. Expression of SDF-1/CXCL-12 in turn, promotes the progression of breast cancer by directly enhancing tumor-cell growth and by recruiting endothelial progenitor cells that are required for tumor angiogenesis. High-level expression of CXCR4 on neoplastic cells is associated with relatively poor overall survival and bad prognosis in patients with breast cancer. The promising results in the preclinical tumor models indicate that CXCR4 antagonists may have to reduce the spread of cancer that is called anti tumor activity in patients with breast cancer. The chemokine receptors CXCR4 antagonists, although initially developed for treatment of acquired immunodeficiency diseases syndrome (AIDS), actually may become effective agents as a molecular targeted therapy for breast cancer.